Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: Long-term predictors from a community-based cohort study

Journal of Clinical Oncology

Volumn 28, Issue 30, 2010, Pages 4587-4593

  Lee, Mei Hsuan ^a   Yang, Hwai I ^a   Lu, Sheng Nan ^a   Jen, Chin Lan ^a   Yeh, Shiou Hwei ^a   Liu, Chun Jen ^a   Chen, Pei Jer ^a   You, San Lin ^a   Wang, Li Yu ^a   Chen, Wei J ^a   Chen, Chien Jen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS RNA; BIOLOGICAL MARKER; HEPATITIS C ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; DEATH CERTIFICATE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; BLOOD; GENETICS; HEPATITIS C; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TAIWAN; TIME; UPREGULATION; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; TAIWAN; TIME FACTORS; UP-REGULATION; VIRAL LOAD;

EID: 78049499788     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.1500     Document Type: Article

References (31)

1. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 345:41-52, 2001 (Pubitemid 32634271)
2. Kim WR: The burden of hepatitis C in the United States. Hepatology 36:S30-S34, 2002 (suppl)
3. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576, 2007 (Pubitemid 46890874)
4. Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030-3044, 2006
5. Chien YC, Jan CF, Kuo HS, et al: Nationwide hepatitis B vaccination program in Taiwan: Effectiveness in the 20 years after it was launched. Epidemiol Rev 28:126-135, 2006
6. Lu SN, Su WW, Yang SS, et al: Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 119:1946-1952, 2006
7. Ghany MG, Strader DB, Thomas DL, et al: Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:1335-1374, 2009
8. Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982, 2002
9. McHutchison JG, Everson GT, Gordon SC, et al: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360:1827-1838, 2009
10. Scott JD, Gretch DR: Molecular diagnostics of hepatitis C virus infection: A systematic review. JAMA 297:724-732, 2007 (Pubitemid 46294562)
11. Hoofnagle JH, Seeff LB: Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355:2444-2451, 2006 (Pubitemid 44903748)
12. Poynard T, Yuen MF, Ratziu V, et al: Viral hepatitis C. Lancet 362:2095-2100, 2003 (Pubitemid 38035201)
13. Bruno S, Crosignani A, Maisonneuve P, et al: Hepatitis c virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: A seventeen-year prospective cohort study. Hepatology 46:1350-1356, 2007 (Pubitemid 350155516)
14. Silini E, Bottelli R, Asti M, et al: Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A case-control study. Gastroenterology 111:199-205, 1996 (Pubitemid 26226900)
15. Sun CA, Farzadegan H, You SL, et al: Mutual confounding and interactive effects between hepatitis C and hepatitis B viral infections in hepatocellular carcinogenesis: A population-based case-control study in Taiwan. Cancer Epidemiol Biomarkers Prev 5:173-178, 1996
16. Tanaka K, Ikematsu H, Hirohata T, et al: Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: Possible role of type 1b (II) infection. J Natl Cancer Inst 88:742-746, 1996 (Pubitemid 26195022)
17. Yates SC, Hafez M, Beld M, et al: Hepatocellular carcinoma in Egyptians with and without a history of hepatitis B virus infection: Association with hepatitis C virus (HCV) infection but not with HCV RNA level. Am J Trop Med Hyg 60:714-720, 1999 (Pubitemid 29233135)
18. Kim WR, Flamm SL, Di Bisceglie AM, et al: Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47: 1363-1370, 2008 (Pubitemid 351547922)
19. Chen CJ, Yang HI, Su J, et al: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73, 2006 (Pubitemid 43042691)
20. Iloeje UH, Yang HI, Jen CL, et al: Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 5:921-931, 2007 (Pubitemid 47161142)
21. Liu CJ, Chuang WL, Lee CM, et al: Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 136:496-504, 2009
22. Yeh SH, Tsai CY, Kao JH, et al: Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 41:659-666, 2004
23. Bruix J, Sherman M, Llovet JM, et al: Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 35:421-430, 2001 (Pubitemid 32844200)
24. Nishiguchi S, Kuroki T, Nakatani S, et al: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055, 1995
25. Yoshida H, Shiratori Y, Moriyama M, et al: Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181, 1999 (Pubitemid 29364999)
26. Lok AS, Seeff LB, Morgan TR, et al: Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136:138-148, 2009
27. Duvoux C, Pawlotsky JM, Bastie A, et al: Low HCV replication levels in end-stage hepatitis C virus-related liver disease. J Hepatol 31:593-597, 1999 (Pubitemid 29487678)
28. Zeuzem S, Diago M, Gane E, et al: Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127:1724-1732, 2004 (Pubitemid 39575851)
29. Wu CH, Lee MF, Kuo HS: Distribution of hepatitis C virus genotypes among blood donors in Taiwan. J Gastroenterol Hepatol 12:625-628, 1997 (Pubitemid 27504877)
30. Poynard T, Ratziu V, Charlotte F, et al: Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 34:730-739, 2001 (Pubitemid 32488789)
31. Afdhal NH, Lok AS, Di Bisceglie AM: Clinical decisions: Management of incidental hepatitis C virus infection. N Engl J Med 360:1902-1906, 2009